Multivalent Antibody Complex Targeting CD99 for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for leukaemias and myelodysplastic syndromes are not entirely effective, with a significant need for improved or alternative treatments that can specifically target and eliminate leukaemia cells.
Innovation Solution
Development of a multivalent antibody complex, specifically a diabody and monoclonal IgG antibodies of the IgG1 and IgG4 classes, capable of recognizing and binding the human protein CD99, which is overexpressed in various types of tumours, including leukaemias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for leukaemias and myelodysplastic syndromes, then treatment is provided, but effectiveness is insufficient and alternative treatments are needed
Solution Approach 1:
The patent segments the therapeutic approach by using multivalent antibody complexes (diabodies with two binding sites) rather than conventional monovalent antibodies or chemotherapy. This segmentation allows simultaneous binding to multiple CD99 molecules on leukaemia cells, enhancing therapeutic effectiveness while providing a novel mechanism distinct from existing treatments.
Solution Approach 2:
The patent changes key parameters of antibody therapy by using multivalent formats (increasing valency from 1 to 2 or more), optimizing affinity for CD99, and engineering specific antibody structures (diabodies, IgG1, IgG4). These parameter changes transform conventional antibody therapy into a more effective treatment specifically tailored for CD99-expressing leukaemias.
2Reliability
If multivalent antibody complexes are developed to specifically target CD99, then therapeutic effectiveness improves, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into modular components (variable regions, constant regions, linkers) that can be independently designed and assembled. The diabody structure segments the antibody into two antigen-binding sites connected by linkers, enabling specific targeting of CD99 while maintaining manageable structural complexity through modular design.
Solution Approach 2:
The patent achieves universality by designing antibody complexes that can target CD99 expressed across multiple leukaemia subtypes (ALL, AML, CLL, CML). The multivalent structure provides multi-functionality by simultaneously engaging multiple CD99 molecules, enhancing binding avidity and therapeutic effectiveness across diverse leukaemia types expressing this common antigen.
3Reliability
If IgG4 variant with high affinity is used, then therapeutic effectiveness increases, but manufacturing and purification complexity increases
Solution Approach 1:
The patent optimizes manufacturing parameters by selecting IgG4 as the antibody class, which has favorable biophysical properties for production and purification. The high affinity of the IgG4 variant for CD99 is achieved through optimized variable region sequences while maintaining the robust expression and purification characteristics of IgG4 antibodies, balancing effectiveness with manufacturability.
Solution Approach 2:
The patent applies local quality by optimizing specific regions of the antibody (variable regions for high affinity binding to CD99) while maintaining standard, well-characterized constant regions (IgG4 Fc portion). This allows the critical binding interface to be customized for maximum effectiveness while the rest of the molecule retains predictable manufacturing and purification properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody complex effectively induces cell death in leukaemia cells by binding to CD99, with the IgG4 variant showing particularly high affinity and therapeutic effectiveness, including the ability to internalize within leukaemia cells.
Implementation Method 1
a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99
Data Source
AI summary
The present invention relates to a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99, a composition comprising said complex and the use thereof for diagnostic purposes and/or for the treatment and/or the follow-up of leukaemias and/or myelodysplastic syndromes. Furthermore, the present invention relates to antibodies, preferably monoclonal, of the immunoglobulins G group type capable of recognizing and binding the human protein CD99, a composition comprising said immunoglobulins and the medical use thereof, in particular for the treatment and/or the follow-up of cancer, preferably solid tumours that express CD99 and/or leukaemias and/or myelodysplastic syndromes.